Lacidipine
From Wikipedia, the free encyclopedia
 |
|
|
Lacidipine
|
|
| Systematic (IUPAC) name | |
| diethyl 2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate | |
| Identifiers | |
| CAS number | ? |
| ATC code | C08 |
| PubChem | |
| Chemical data | |
| Formula | C26H33NO6 |
| Mol. mass | 455.543 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Lacidipine (tradenames Lacipil (GSK) or Motens (Boehringer Ingelheim)) is a calcium channel blocker. It is available as tablets containing 2 or 4 mg.
[edit] External links
- Motens 2 mg Summary of Product Characteristics
- Motens 4 mg Summary of Product Characteristics
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
